These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 27587597)

  • 1. A two-stage model in a Bayesian framework to estimate a survival endpoint in the presence of confounding by indication.
    Bellera C; Proust-Lima C; Joseph L; Richaud P; Taylor J; Sandler H; Hanley J; Mathoulin-Pélissier S
    Stat Methods Med Res; 2018 Apr; 27(4):1271-1281. PubMed ID: 27587597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Ann Epidemiol; 2008 Apr; 18(4):270-82. PubMed ID: 18374279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of treatment efficacy using a Bayesian mixture piecewise linear model of longitudinal biomarkers.
    Zhao L; Feng D; Neelon B; Buyse M
    Stat Med; 2015 May; 34(10):1733-46. PubMed ID: 25630845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A statistical evaluation of rules for biochemical failure after radiotherapy in men treated for prostate cancer.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1357-63. PubMed ID: 19395198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-time individual predictions of prostate cancer recurrence using joint models.
    Taylor JM; Park Y; Ankerst DP; Proust-Lima C; Williams S; Kestin L; Bae K; Pickles T; Sandler H
    Biometrics; 2013 Mar; 69(1):206-13. PubMed ID: 23379600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial.
    Pollack A; Zagars GK; Antolak JA; Kuban DA; Rosen II
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):677-85. PubMed ID: 12377318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
    Pauler DK; Finkelstein DM
    Stat Med; 2002 Dec; 21(24):3897-911. PubMed ID: 12483774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy.
    Sandler HM; Dunn RL; McLaughlin PW; Hayman JA; Sullivan MA; Taylor JM
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):629-33. PubMed ID: 11020557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in postoperative radiotherapy for prostate cancer - tertiary center experience.
    Miszczyk M; Majewski W; Stawiski K; Rasławski K; Rajwa P; Jabłońska I; Magrowski Ł; Masri O; Paradysz A; Miszczyk L
    Radiol Oncol; 2021 Mar; 55(2):203-211. PubMed ID: 33768769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma.
    Aref I; Eapen L; Agboola O; Cross P
    Radiother Oncol; 1998 Aug; 48(2):203-7. PubMed ID: 9783893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
    Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
    J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical application of biochemical failure definitions: what to do and when to do it.
    Kestin LL; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):304-15. PubMed ID: 12023134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability of prostate-specific antigen-marker in determining biochemical failure during the first 2 years after external beam radiation therapy and hormone therapy in patients with non-operated prostate cancer.
    Vigna-Taglianti R; Russi EG; Boriano A; Gianello L; Denaro N; Lucio F; Arena G; Buglione M; Pergolizzi S; Ricardi U; Magrini S
    Urol Oncol; 2014 Jan; 32(1):30.e1-7. PubMed ID: 23410946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting trends in noisy data series: application to biomarker series.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Am J Epidemiol; 2008 May; 167(9):1130-9. PubMed ID: 18303004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
    Lee WR; Hanlon AL; Hanks GE
    J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.